SG11201605784YA - Cell surface prostate cancer antigen for diagnosis - Google Patents

Cell surface prostate cancer antigen for diagnosis

Info

Publication number
SG11201605784YA
SG11201605784YA SG11201605784YA SG11201605784YA SG11201605784YA SG 11201605784Y A SG11201605784Y A SG 11201605784YA SG 11201605784Y A SG11201605784Y A SG 11201605784YA SG 11201605784Y A SG11201605784Y A SG 11201605784YA SG 11201605784Y A SG11201605784Y A SG 11201605784YA
Authority
SG
Singapore
Prior art keywords
diagnosis
cell surface
prostate cancer
cancer antigen
surface prostate
Prior art date
Application number
SG11201605784YA
Other languages
English (en)
Inventor
Bradley Walsh
Douglas Campbell
Fuenmayor Irene Justiniano
Aline Nocon
Julie Soon
Quach Truong
Sandra Wissmueller
Pamela Russell
Original Assignee
Minomic Internat Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minomic Internat Ltd filed Critical Minomic Internat Ltd
Publication of SG11201605784YA publication Critical patent/SG11201605784YA/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21077—Semenogelase (3.4.21.77), i.e. prostate specific antigen or PSA or kallikrein 3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96433—Serine endopeptidases (3.4.21)
    • G01N2333/96441—Serine endopeptidases (3.4.21) with definite EC number
    • G01N2333/96455—Kallikrein (3.4.21.34; 3.4.21.35)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/38—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence, e.g. gluco- or galactomannans, e.g. Konjac gum, Locust bean gum, Guar gum
    • G01N2400/40—Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
SG11201605784YA 2014-01-17 2015-01-16 Cell surface prostate cancer antigen for diagnosis SG11201605784YA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461928776P 2014-01-17 2014-01-17
PCT/AU2015/000018 WO2015106311A1 (fr) 2014-01-17 2015-01-16 Antigène de surface cellulaire du cancer de la prostate destiné au diagnostic

Publications (1)

Publication Number Publication Date
SG11201605784YA true SG11201605784YA (en) 2016-08-30

Family

ID=53542211

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201605784YA SG11201605784YA (en) 2014-01-17 2015-01-16 Cell surface prostate cancer antigen for diagnosis

Country Status (12)

Country Link
US (2) US10151754B2 (fr)
EP (1) EP3094976B1 (fr)
JP (2) JP6691060B2 (fr)
KR (1) KR102366820B1 (fr)
CN (1) CN106164672B (fr)
AU (1) AU2015207665B2 (fr)
CA (1) CA2936805C (fr)
DK (1) DK3094976T3 (fr)
ES (1) ES2803217T3 (fr)
HK (1) HK1225791A1 (fr)
SG (1) SG11201605784YA (fr)
WO (1) WO2015106311A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6749901B2 (ja) * 2014-10-23 2020-09-02 グリピー ホールディングス ピーティーワイ リミテッド モノクローナル抗ｇｐｃ−１抗体およびその使用
CN107847593B (zh) * 2015-04-20 2021-12-14 美侬米克国际有限公司 治疗抗体及其用途
CN106053815B (zh) * 2016-07-01 2018-03-27 复旦大学附属中山医院 Gpc1作为肿瘤诊断标志物的用途
EP3617231A4 (fr) * 2017-04-28 2021-04-07 National University Corporation Kochi University Anticorps anti-gpc-1
CN107907684A (zh) * 2017-09-29 2018-04-13 何皓 一种基于多重荧光寿命分辨检测技术的前列腺癌早期诊断系统
CN111187350A (zh) * 2019-12-30 2020-05-22 西安英创生物技术有限公司 一种与磷脂酰肌醇蛋白聚糖-1结合的抗原结合蛋白
JP7053058B2 (ja) * 2020-05-28 2022-04-12 グリピー ホールディングス ピーティーワイ リミテッド グリピカンエピトープおよびその使用
WO2024075067A1 (fr) * 2022-10-06 2024-04-11 Centro Di Riferimento Oncologico Composition de vaccin contre le cancer qui comprend une cellule hôte exprimant le glypican-1 (gpc-1)

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE337223B (fr) 1967-05-23 1971-08-02 Pharmacia Ab
US3720760A (en) 1968-09-06 1973-03-13 Pharmacia Ab Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples
US3691016A (en) 1970-04-17 1972-09-12 Monsanto Co Process for the preparation of insoluble enzymes
CA1023287A (fr) 1972-12-08 1977-12-27 Boehringer Mannheim G.M.B.H. Procede de fixation d'une proteine sur un substrat
US4195128A (en) 1976-05-03 1980-03-25 Bayer Aktiengesellschaft Polymeric carrier bound ligands
US4330440A (en) 1977-02-08 1982-05-18 Development Finance Corporation Of New Zealand Activated matrix and method of activation
CA1093991A (fr) 1977-02-17 1981-01-20 Hideo Hirohara Traduction non-disponible
US4229537A (en) 1978-02-09 1980-10-21 New York University Preparation of trichloro-s-triazine activated supports for coupling ligands
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US5622836A (en) 1989-05-24 1997-04-22 The University Of Sydney Monoclonal antibodies which recognize malignant cells from bladder carcinomas
US6116013A (en) 1998-01-02 2000-09-12 Siemens Westinghouse Power Corporation Bolted gas turbine combustor transition coupling
US7108986B2 (en) * 1998-10-16 2006-09-19 The Regents Of The University Of California Glypican-1 in human breast cancer
JP4381140B2 (ja) 2001-10-12 2009-12-09 シェーリング コーポレイション 免疫応答を調節するための二重特異性抗体の使用
WO2004022597A1 (fr) * 2002-09-04 2004-03-18 Chugai Seiyaku Kabushiki Kaisha Anticorps d'un peptide n-terminal du gpc3 solubilise dans le sang
AU2002330482A1 (en) * 2002-09-04 2004-03-29 Perseus Proteomics Inc. Method of diagnosing cancer by detecting gpc3
KR20130103580A (ko) * 2004-08-24 2013-09-23 추가이 세이야쿠 가부시키가이샤 항 글리피칸 3 항체를 이용한 어쥬번트 요법
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
US7723043B2 (en) * 2006-01-04 2010-05-25 Picobella, Lp Methods for screening for prostate cancer
WO2008060607A2 (fr) 2006-11-14 2008-05-22 Biosite Incorporated Procédés et compositions permettant de surveiller et de prévoir les risques du syndrome cardio-rénal
CA2675639A1 (fr) * 2007-02-02 2008-08-07 Novartis Ag Modulateurs de partenaires de liaison de la sclerostine pour traiter des troubles lies aux os
EP2156184B1 (fr) 2007-05-08 2013-11-27 Picobella, LLC Procedes de diagnostic et de traitement du cancer de la prostate et du cancer du poumon
KR101105428B1 (ko) * 2009-02-12 2012-01-17 경북대학교 산학협력단 글리피칸-3 단백질과 특이적으로 결합하는 펩타이드
WO2013119964A2 (fr) 2012-02-08 2013-08-15 Stem Centrx, Inc. Identification et enrichissement de sous-populations cellulaires
AU2012253204A1 (en) * 2011-05-06 2013-04-18 Women's And Children's Health Research Institute Inc Method of treatment and prophylaxis of pathologies of the bone

Also Published As

Publication number Publication date
EP3094976A1 (fr) 2016-11-23
KR102366820B1 (ko) 2022-02-22
JP2017504812A (ja) 2017-02-09
CA2936805C (fr) 2024-02-20
WO2015106311A1 (fr) 2015-07-23
ES2803217T3 (es) 2021-01-25
US20190120846A1 (en) 2019-04-25
JP6691060B2 (ja) 2020-04-28
EP3094976B1 (fr) 2020-03-25
KR20160114088A (ko) 2016-10-04
US10151754B2 (en) 2018-12-11
US20160349263A1 (en) 2016-12-01
AU2015207665B2 (en) 2021-04-15
DK3094976T3 (da) 2020-06-22
CA2936805A1 (fr) 2015-07-23
HK1225791A1 (zh) 2017-09-15
CN106164672A (zh) 2016-11-23
JP2020060585A (ja) 2020-04-16
CN106164672B (zh) 2018-08-28
AU2015207665A1 (en) 2016-08-04
EP3094976A4 (fr) 2017-07-05

Similar Documents

Publication Publication Date Title
IL290459A (en) Modified t cells - targeted chimeric antigen receptor cs1
ZA201702382B (en) Combination therapy for cancer
ZA201701753B (en) Biomarkers for assessing breast cancer
SG11201605585SA (en) Targeted therapy for small cell lung cancer
EP3189082A4 (fr) Conjugués anti-pd-l1 pour le traitement des tumeurs
HUE054397T2 (hu) Antitestkészítmények daganatkezelésre
HK1225791A1 (zh) 用於診斷的細胞表面前列腺癌抗原
IL273265A (en) New combinations for antigen-based therapy
GB201420859D0 (en) Tumour analysis
HK1231381A1 (zh) 癌症組合療法
IL246761A0 (en) Combined cancer treatment
HUE057708T2 (hu) Sejtek humán antitestek elõállítására
SG11201702077RA (en) Kit for cancer detection
GB201508480D0 (en) Cancer
GB2528304B (en) Perineal prostate biopsy apparatus
IL247723A0 (en) Compounds that target cancer stem cells
GB201407003D0 (en) Biomarkers for prostate cancer
GB201402559D0 (en) Biomarkers for prostate cancer
GB201506666D0 (en) Biomarkers for prostate cancer
GB201400373D0 (en) Biomarker panel for prostate cancer
GB201405286D0 (en) Cancer diagnostic
GB201417819D0 (en) Agents for cancer therapy
GB201400387D0 (en) Diagnostic for gastric cancer
GB201411884D0 (en) Cancer therapy